Cabaletta appoints ex-Kite Pharma CCO Shawn Tomasello to board; updates DSG3-CAART data

Cabaletta Bio, Inc.

Shawn Tomasello, former Kite Pharma CCO, appointed to board effective July 21, 2023.
Tomasello granted option for 44,000 shares at $13.48, vesting quarterly over three years.
DSG3-CAART combination sub-study shows modestly increased persistence with cyclophosphamide pretreatment.
New DSG3-CAART cohort initiated adding fludarabine to regimen to improve engraftment.
Company reiterates guidance for CABA-201 3-month clinical data by first half of 2024.

item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Shawn Tomasello

Director

CABA · Cabaletta Bio, Inc.

Effective: 2023-07-21
Filed: July 24, 2023, 7:59 PM ET

On July 21, 2023, upon the recommendation of its Nominating and Corporate Governance Committee (the “NCG Committee”), the Board of Directors (the “Board”) of Cabaletta Bio, Inc. (the “Company”) appointed Shawn Tomasello to join the Board, effective as of July 21, 2023 (the “Effective Date”), to fill the newly created vacancy on the Board resulting from an increase in the size of the Board from five (5) to six (6) directors.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Shawn Tomasello was appointed as Director at Cabaletta Bio, Inc..

Action: appointed
Role: Director

Exact text from the filing

On July 21, 2023, upon the recommendation of its Nominating and Corporate Governance Committee (the “NCG Committee”), the Board of Directors (the “Board”) of Cabaletta Bio, Inc. (the “Company”) appointed Shawn Tomasello to join the Board, effective as of July 21, 2023 (the “Effective Date”), to fill the newly created vacancy on the Board resulting from an increase in the size of the Board from five (5) to six (6) directors.

View on SEC.gov

Cabaletta Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-191895

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.